

Women's Health Therapeutics, Analysis and Market
Forecasts to 2016 - High Unmet Need will Drive the
Uptake of Novel Drugs in the Menopause and
Osteoporosis Markets

Phone: +44 20 8123 2220

Fax: +44 207 900 3970

office@marketpublishers.com

<http://marketpublishers.com>

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

GBI Research

Date: Aug, 2010

Pages: 132

Price: US\$ 3,500.00

ID: W10CC681564EN

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Summary

GBI Research's report, "Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global women's health market. The report analyzes the markets for women's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data for the women's health market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, women's infertility and polycystic ovarian syndrome.
- Analysis of the women's health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the women's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Content

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 GLOBAL WH DISORDER THERAPEUTICS MARKET:INTRODUCTION

- 2.1 GBI Research Report Guidance

3 GLOBAL WH DISORDER THERAPEUTICS MARKET: MARKET CHARACTERIZATION

- 3.1 Introduction
- 3.2 Revenue Forecasts for the Global WH Disorder Therapeutics Market
 - 3.2.1 Sales Value
 - 3.2.2 Annual Cost of Therapy
 - 3.2.3 Treatment Usage Patterns
 - 3.2.4 Generics' Share in the Global WH Disorder Therapeutics Market

4 GLOBAL WH DISORDER THERAPEUTICS MARKET: THERAPEUTIC LANDSCAPE

- 4.1 Global Menopause Therapeutics Market
 - 4.1.1 Introduction
 - 4.1.2 Sales Value
 - 4.1.3 Annual Cost of Therapy
 - 4.1.4 Treatment Usage Patterns
 - 4.1.5 Drivers and Barriers for the Menopause Therapeutics Market
 - 4.1.6 Market share by Geography
 - 4.1.7 Product Analysis
- 4.2 Global Endometriosis Therapeutics Market
 - 4.2.1 Introduction
 - 4.2.2 Sales Value
 - 4.2.3 Annual Cost of Therapy
 - 4.2.4 Treatment Usage Patterns
 - 4.2.5 Drivers and Barriers for the Endometriosis Therapeutics Market
 - 4.2.6 Market share by Geography
 - 4.2.7 Product Analysis
- 4.3 Global Postmenopausal Osteoporosis (PMO) Market
 - 4.3.1 Introduction
 - 4.3.2 Sales Value
 - 4.3.3 Annual Cost of Therapy
 - 4.3.4 Treatment Usage Patterns
 - 4.3.5 Drivers and Barriers for the Menopause Therapeutics Market
 - 4.3.6 Market Share by Geography

4.3.7 Product Analysis

5 GLOBAL WH DISORDER THERAPEUTICS MARKET: GEOGRAPHICAL LANDSCAPE

5.1 Geographical Break-up

5.2 The US

5.2.1 Sales Value

5.2.2 Annual Cost of Therapy

5.2.3 Treatment Usage Patterns

5.3 Top Five Markets in Europe

5.3.1 Sales Value

5.3.2 Annual Cost of Therapy

5.3.3 Treatment Usage Patterns

5.4 Japan

5.4.1 Sales Value

5.4.2 Annual Cost of Therapy

5.4.3 Treatment Usage Patterns

6 GLOBAL WH DISORDER THERAPEUTICS MARKET: PIPELINE ANALYSIS

6.1 Introduction

6.1.1 Research and Development Pipeline – Menopause

6.1.2 Research and Development Pipeline – Endometriosis

6.1.3 Research and Development Pipeline - Postmenopausal Osteoporosis

6.2 Profiles of Key Late-Stage Drugs in the WH disorder Therapeutics Market

6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen)

6.2.2 Pristiq (Desvenlafaxine, DVS-233)

6.2.3 Visanne

6.2.4 Elagolix (NBI-56418)

6.2.5 Odanacatib (MK-0822)

6.2.6 Viviant (Bazedoxifene)

7 GLOBAL WH DISORDER THERAPEUTICS MARKET: COMPETITIVE LANDSCAPE

7.1 Market Share Analysis: Women's Health

7.2 Competitive Profiling

7.2.1 Pfizer Inc

7.3 Eli Lilly and Company

7.4 Merck & Co.

7.5 Procter & Gamble Company

7.6 Hoffmann-La Roche Ltd.

8 GLOBAL WH DISORDER THERAPEUTICS MARKET: STRATEGIC CONSOLIDATIONS

8.1 Mergers and Acquisitions

8.1.1 Overview

8.1.2 Ferring Pharmaceuticals Acquires Global Rights to LYSTEDA from Xanodyne Pharmaceuticals in May 2010

8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010

8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010

8.1.5 Sciele Pharma Acquires Addrenex Pharmaceuticals in November 2009

8.1.6 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009

8.1.7 BioSante Pharmaceuticals Merges with Cell Genesys in October 2009

8.1.8 Hisamitsu Pharmaceutical Completes Acquisition Of Noven Pharmaceuticals in August 2009

8.1.9 Pfizer Acquires Wyeth in January 2009

8.1.10 Par Pharmaceuticals Acquires Assets Of Calcitonin & A Manufacturing Facility From MDRNA in April 2009

8.2 R&D Licensing Agreements

8.2.1 Deals by Indication

8.2.2 Deals by Phase

8.2.3 Deals by Geography

9 GLOBAL WH DISORDER THERAPEUTICS MARKET: APPENDIX

9.1 Market Definitions

9.2 Abbreviations

9.3 Coverage

9.3.1 Secondary Research

9.3.2 Primary Research

9.3.3 Forecasts

9.3.4 Expert Panel Validation

9.4 Contact Us

9.5 Disclaimer

9.6 Sources

LIST OF TABLES

Table 1: WH Disorder Therapeutics Market, Global, Sales Value (\$bn), 2001–2009

Table 2: WH Disorder Therapeutics Market, Global, Sales Value (\$bn), 2009–2016

Table 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy (\$), 2001–2009

Table 4: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy (\$), 2009–2016

Table 5: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2001–2009

Table 6: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2009–2016

Table 7: WH Disorder Therapeutics Market, Global, Menopause Sales Value (\$bn), 2001–2009

Table 8: WH Disorder Therapeutics Market, Global, Menopause Sales Value (\$bn), 2009–2016

Table 9: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy (\$), 2001–2009

Table 10: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy (\$), 2009–2016

Table 11: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2001–2009

Table 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2009–2016

Table 13: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value (\$bn), 2001–2009

Table 14: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value (\$bn), 2009–2016

Table 15: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy (\$), 2001–2009

Table 16: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy (\$), 2009–2016

Table 17: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2001–2009

Table 18: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2009–2016

Table 19: WH Disorder Therapeutics Market, Global, PMO Sales Value (\$bn), 2001–2009

Table 20: WH Disorder Therapeutics Market, Global, PMO Sales Value (\$bn), 2009–2016

Table 21: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy (\$), 2001–2009

Table 22: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy (\$), 2009–2016

Table 23: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2009

Table 24: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2009–2016

Table 25: WH Disorder Therapeutics Market, Global, Sales Value by Geography (\$bn), 2001–2009

Table 26: WH Disorder Therapeutics Market, Global, Sales Value by Geography (\$bn), 2009–2016

Table 27: WH Disorder Therapeutics Market, The US, Sales Value (\$bn), 2001–2009

Table 28: WH Disorder Therapeutics Market, The US, Sales Value (\$bn), 2009–2016

Table 29: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy (\$), 2001–2009

Table 30: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy (\$), 2009–2016

Table 31: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2009

Table 32: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2009–2016

Table 33: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value (\$bn), 2001–2009

Table 34: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value (\$bn), 2009–2016

Table 35: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy (\$), 2001–2009

Table 36: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy (\$), 2009–2016

Table 37: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2001–2009

Table 38: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2009–2016

Table 39: WH Disorder Therapeutics Market, Japan, Sales Value (\$bn), 2001–2009

Table 40: WH Disorder Therapeutics Market, Japan, Sales Value (\$bn), 2009–2016

Table 41: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy (\$), 2001–2009

Table 42: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy (\$), 2009–2016

Table 43: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2009

Table 44: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2009–2016

Table 45: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase III Pipeline, August 2010

Table 46: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase II Pipeline, August 2010

Table 47: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase I Pipeline, August 2010

Table 48: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Preclinical Pipeline, August 2010

Table 49: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase III and Regulatory Filing, August 2010

Table 50: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase II Pipeline, August 2010

Table 51: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase I Pipeline, August 2010

Table 52: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Preclinical Pipeline, August 2010

Table 53: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase III and Regulatory Filing, August 2010

Table 54: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase II Pipeline, August 2010

Table 55: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase I Pipeline, August 2010

Table 56: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Preclinical Pipeline, August 2010

Table 57: WH Disorder Therapeutics Market, Global, Major M&A Deals, 2009–2010

LIST OF FIGURES

Figure 1: Women's Health Market, Global, Drivers and Restraints, 2009

Figure 2: WH Disorder Therapeutics Market, Global, Sales Value (\$bn), 2001–2016

Figure 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy (\$), 2001–2016

Figure 4: WH Disorder Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016

- Figure 5: WH Disorder Therapeutics Market, Global, Diseased Population (in millions), 2001–2016
- Figure 6: WH Disorder Therapeutics Market, Global, Treatment Seeking Population (in millions), 2001–2016
- Figure 7: WH Disorder Therapeutics Market, Global, Diagnosed Population (in millions), 2001–2016
- Figure 8: WH Disorder Therapeutics Market, Global, Prescription Population (in millions), 2001–2016
- Figure 9: WH Disorder Therapeutics Market, Global, Branded v/s Generic Drugs, \$bn, 2001–2016
- Figure 10: WH Disorder Therapeutics Market, Global, Menopause Sales Value (\$bn), 2001–2016
- Figure 11: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy (\$), 2001–2016
- Figure 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (million), 2001–2016
- Figure 13: WH Disorder Therapeutics Market, Global, Menopause Diseased Population (in millions), 2001–2016
- Figure 14: WH Disorder Therapeutics Market, Global, Menopause Treatment Seeking Population (in millions), 2001–2016
- Figure 15: WH Disorder Therapeutics Market, Global, Menopause Diagnosis Population (in millions), 2001–2016
- Figure 16: WH Disorder Therapeutics Market, Global, Menopause Prescription Population (in millions), 2001–2016
- Figure 17: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2009 and 2016
- Figure 18: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2001 - 2016
- Figure 19: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value (\$bn), 2001–2016
- Figure 20: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy (\$), 2001–2016
- Figure 21: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (million), 2001–2016
- Figure 22: WH Disorder Therapeutics Market, Global, Endometriosis Diseased Population (in millions), 2001–2016
- Figure 23: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Seeking Population (in millions), 2001–2016
- Figure 24: WH Disorder Therapeutics Market, Global, Endometriosis Diagnosis Population (in millions), 2001–2016
- Figure 25: WH Disorder Therapeutics Market, Global, Endometriosis Prescription Population (in millions), 2001–2016
- Figure 26: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2009 and 2016
- Figure 27: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2001 - 2016
- Figure 28: WH Disorder Therapeutics Market, Global, PMO Sales Value (\$bn), 2001–2016
- Figure 29: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy (\$), 2001–2016
- Figure 30: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2016
- Figure 31: WH Disorder Therapeutics Market, Global, PMO Diseased Population (in millions), 2001–2016
- Figure 32: WH Disorder Therapeutics Market, Global, PMO Treatment Seeking Population (in millions), 2001–2016
- Figure 33: WH Disorder Therapeutics Market, Global, PMO Diagnosis Population (in millions), 2001–2016
- Figure 34: WH Disorder Therapeutics Market, Global, PMO Prescription Population (in millions), 2001–2016
- Figure 35: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009 and 2016
- Figure 36: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009–2016
- Figure 37: WH Disorder Therapeutics Market, Global, Market Share by Geography, 2009 and 2016
- Figure 38: WH Disorder Therapeutics Market, Global, Sales Value by Geography (\$bn), 2001–2016

- Figure 39: WH Disorder Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016
- Figure 40: WH Disorder Therapeutics Market, US, Sales Value (\$bn), 2001–2016
- Figure 41: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy (\$), 2001–2016
- Figure 42: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2016
- Figure 43: WH Disorder Therapeutics Market, The US, Diseased Population (in millions), 2001–2016
- Figure 44: WH Disorder Therapeutics Market, The US, Treatment Seeking Population (in millions), 2001–2016
- Figure 45: WH Disorder Therapeutics Market, The US, Diagnosis Population (in millions), 2001–2016
- Figure 46: WH Disorder Therapeutics Market, The US, Prescription Population (in millions), 2001–2016
- Figure 47: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value (\$bn), 2001–2016
- Figure 48: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy (\$), 2001–2016
- Figure 49: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Patterns (in millions), 2001–2016
- Figure 50: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diseased Population (in millions), 2001–2016
- Figure 51: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Seeking Population (in millions), 2001–2016
- Figure 52: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diagnosis Population (in millions), 2001–2016
- Figure 53: WH Disorder Therapeutics Market, Top Five Markets in Europe, Prescription Population (in millions), 2001–2016
- Figure 54: WH Disorder Therapeutics Market, Japan, Sales Value (\$m), 2001–2016
- Figure 55: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy (\$), 2001–2016
- Figure 56: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2016
- Figure 57: WH Disorder Therapeutics Market, Japan, Diseased Population (in millions), 2001–2016
- Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 2001–2016
- Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 2001–2016
- Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 2001–2016
- Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010
- Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010
- Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010
- Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010
- Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010
- Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009
- Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players (\$m), 2009
- Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players (\$m), 2009
- Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009
- Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009
- Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009
- Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009
- Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009
- Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010
- Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009
- Figure 76: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Value (%), 2009
- Figure 77: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2004–2010
- Figure 78: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Phase (%), 2004–2010
- Figure 79: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Geography (%),

2009–2010

Figure 80: GBI Research Market Forecasting Model, 2010

COMPANIES MENTIONED

Eli Lilly and Company

Merck & Co.

Procter & Gamble Company

Hoffmann-La Roche Ltd.

Pfizer Inc

I would like to order:

Product name: Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Product link: <http://marketpublishers.com/r/W10CC681564EN.html>

Product ID: W10CC681564EN

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/W10CC681564EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**

